Decision Criterion and Value of Information Analysis: Optimal Aspirin Dosage for Secondary Prevention of Cardiovascular Events

被引:10
|
作者
Basu, Anirban [1 ,2 ,3 ]
Meltzer, David [4 ,5 ]
机构
[1] Univ Washington, Dept Pharm, Comparat Hlth Outcome Policy & Econ CHOICE Inst, 1959 NE Pacific St,Box 357660, Seattle, WA 98195 USA
[2] Univ Washington, Dept Hlth Serv, 1959 NE Pacific St,Box 357660, Seattle, WA 98195 USA
[3] Univ Washington, Dept Econ, 1959 NE Pacific St,Box 357660, Seattle, WA 98195 USA
[4] Univ Chicago, Dept Med, Harris Sch Publ Policy Studies, Sect Hosp Med, 5841 S Maryland Ave, Chicago, IL 60637 USA
[5] Univ Chicago, Dept Econ, Chicago, IL 60637 USA
关键词
aspirin; cardiovascular; decision criterion; value of information; ACUTE MYOCARDIAL-INFARCTION; COLLABORATIVE METAANALYSIS; IMPLEMENTATION; DISEASE;
D O I
10.1177/0272989X17746988
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background. In value of information (VOI) calculations, such as the expected value of perfect information (EVPI), partial perfect information (EVPPI), sample information (EVSI) or implementation (EVIM), the maximum expected value criterion defines the decision making criterion for the adoption of decisions for treatments. However, because decision makers are often risk averse, the uncertainty that accompanies a decision problem may influence adoption decisions. Methods. VOI estimates were studied based on 2 alternate decision making criteria: 1) maximum expected value and 2) 95% credible intervals. These criteria were applied to a probabilistic minimal lifetime model of incident cardiovascular events and mortality among target patients comparing 2 daily doses of aspirin (81 mg and 325 mg). Model parameters were based on literature reviews and data analyses. Results. Expected life-years under 81 v. 325 mg of aspirin were estimated to be 14.86 (SE, 0.10) and 14.72 (0.31) respectively, with a difference of 0.14 (0.29). The probability that 81 mg was optimal was estimated to be 67%. Under Decision Criterion 1, EVIM and EVPI were about 233-thousand and 411-thousand years, respectively. Under Criterion 2, EVIM was undefined, as there remains ambiguity about what to implement. Consequently, EVPI becomes the entire 644-thousand years. Also, under Criterion 1, EVSI reaches an asymptote at a sample size of 10,000 per arm, with minimal gains in value beyond a 5,000 person per arm trial. With Criterion 2, a sample size of 10,000 per arm or higher is substantially more valuable than lower sample sizes. Conclusion. Alternative decision criteria for treatment adoption change the VOI. Decision criteria should be justified for VOI analyses. If multiple criteria may be relevant, analysts should complete VOI estimates using multiple criteria.
引用
收藏
页码:427 / 438
页数:12
相关论文
共 50 条
  • [41] Thienopyridines or aspirin for secondary prevention of vascular events?
    Mason, G
    Sudlow, C
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2006, 77 (01): : 138 - 138
  • [42] Aspirin for Primary and Secondary Prevention of Cardiovascular Disease
    Godley, Robert W.
    Hernandez-Vila, Eduardo
    TEXAS HEART INSTITUTE JOURNAL, 2016, 43 (04): : 318 - 319
  • [43] OPTIMAL ASPIRIN DOSAGE FOR PREVENTION OF HEART-DISEASE AND STROKES
    MCGIVNEY, WT
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1984, 251 (01): : 89 - 90
  • [44] Low-dose aspirin for primary and secondary prevention of cardiovascular events in Denmark 1998–2018
    Mikkel B. Christensen
    Espen Jimenez-Solem
    Martin. T. Ernst
    Morten Schmidt
    Anton Pottegård
    Erik L. Grove
    Scientific Reports, 11
  • [45] Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events
    Weisman, SM
    Graham, DY
    ARCHIVES OF INTERNAL MEDICINE, 2002, 162 (19) : 2197 - 2202
  • [46] LONG-TERM COST-EFFECTIVENESS OF ADHERENCE TO ASPIRIN FOR SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS
    Djatche, L.
    Varga, S.
    Liebertal, R.
    VALUE IN HEALTH, 2017, 20 (05) : A9 - A9
  • [47] Aspirin for primary prevention of cardiovascular events in diabetes: Is there a place?
    Benhamou, Y.
    Levesque, H.
    REVUE DE MEDECINE INTERNE, 2009, 30 (12): : 1001 - 1003
  • [48] Role of aspirin for prevention and treatment of perioperative cardiovascular events
    Duceppe, E.
    Mrkobrada, M.
    Thomas, S.
    Devereaux, P. J.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : S297 - S303
  • [49] Primary prevention of cardiovascular events in diabetes: is there a role for aspirin?
    Price, Hermione C.
    Holman, Rury R.
    NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE, 2009, 6 (03): : 168 - 169
  • [50] Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis
    Zhang, Chunyu
    Sun, Aijun
    Zhang, Peng
    Wu, Chaoneng
    Zhang, Shuning
    Fu, Mingqiang
    Wang, Keqiang
    Zou, Yunzeng
    Ge, Junbo
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2010, 87 (02) : 211 - 218